AgenT
PrivateCompany Overview
AgenT is a biotechnology company that develops a blood-based multiomics platform for the early detection and monitoring of neurodegenerative diseases, including Alzheimer's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AgenT Comparables
Compare AgenT with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| C2N Diagnostics | 85% | |
| Point6 Bio | 80% | |
| ALZpath, Inc. | 80% | |
AgenT Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 22, 2026
Grew 56% QoQ, from 25 to 39 employees.
AgenT Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AgenT's valuation, stock price, and market status.